Search

Your search keyword '"Sharmin , S."' showing total 1,243 results
Start Over Author "Sharmin , S."
1,243 results on '"Sharmin , S."'

152. Modelling of Infectious Diseases for Providing Signal of Epidemics: A Measles Case Study in Bangladesh

Author

Sharmin, S, Rayhan, I, Sharmin, S, and Rayhan, I

Abstract

The detection of unusual patterns in the occurrence of diseases is an important challenge to health workers interested in early identification of epidemics. The objective of this study was to provide an early signal of infectious disease epidemics by analyzing the disease dynamics. A two-stage monitoring system was applied, which consists of univariate Box-Jenkins model or autoregressive integrated moving average model and subsequent tracking signals from several statistical process-control charts. The analyses were illustrated on January 2000-August 2009 national measles data reported monthly to the Expanded Programme on Immunization (EPI) in Bangladesh. The results of this empirical study revealed that the most adequate model for the occurrences of measles in Bangladesh was the seasonal autoregressive integrated moving average (3, 1, 0) (0, 1, 1)12 model, and the statistical process-control charts detected no measles epidemics during September 2007-August 2009. The two-stage monitoring system performed well to capture the measles dynamics in Bangladesh without detection of an epidemic because of high measles-vaccination coverage.

Published
2011

155. Length-weight and length-length relationships of five Mystus species from the Ganges and Rupsha rivers, Bangladesh.

Author

Hossain, M. Y., Hossen, M. A., Pramanik, M. N. U., Sharmin, S., Nawer, F., Naser, S. M. A., Bahkali, A. H., and Elgorban, A. M.

Subjects
GILLNETTING, RIVERS, BODY weight, ECOSYSTEMS, SPECIES hybridization
Abstract

This study focused on the length-weight and length-length relationships of five Mystus species from Bangladesh. A sum of 398 individuals ( Mystus bleekeri = 47, Mystus cavasius = 171, Mystus gulio = 59, Mystus tengra = 65, and Mystus vittatus = 56) was collected from the Ganges and Rupsha rivers, Bangladesh. Fishes were caught by gill net (mesh sizes: 2.0-4.0 cm) and cast net (mesh sizes: 1.5-3.0 cm) from July 2014 to June 2015. Total length ( TL), fork length ( FL) and standard length ( SL) were measured to 0.1 cm, while whole body weight ( W) was taken to the nearest 0.1 g for each individual. The TL ranged from 6.0-13.5 cm for M. bleekeri, 5.0-15.0 cm for M. cavasius, 7.4-17.2 cm for M. gulio, 4.6-11.6 cm for M. tengra and 5.5-12.3 cm for M. vittatus. The W varied from 3.0-18.2 g for M. bleekeri, 1.3-30.4 g for M. cavasius, 6.1-62.2 g for M. gulio, 1.7-15.1 g for M. tengra and 2.7-19.2 g for M. vittatus. All LWRs were highly significant ( p < .001), with all r 2 values ≥.950. The LLRs were also highly significant ( p < .001), with all r 2 ≥.980. This study provides information on LWRs and LLRs for M. gulio and M. tengra for the first time. The results of this study can be very effective for stock assessment of Mystus species in the Ganges and Rupsha rivers as well as in the surrounding ecosystems. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

172. Modelling of infectious diseases for providing signal of epidemics: a measles case study in Bangladesh.

Author

Sharmin S, Rayhan I, Sharmin, Sifat, and Rayhan, Israt

Abstract

The detection of unusual patterns in the occurrence of diseases is an important challenge to health workers interested in early identification of epidemics. The objective of this study was to provide an early signal of infectious disease epidemics by analyzing the disease dynamics. A two-stage monitoring system was applied, which consists of univariate Box-Jenkins model or autoregressive integrated moving average model and subsequent tracking signals from several statistical process-control charts. The analyses were illustrated on January 2000-August 2009 national measles data reported monthly to the Expanded Programme on Immunization (EPI) in Bangladesh. The results of this empirical study revealed that the most adequate model for the occurrences of measles in Bangladesh was the seasonal autoregressive integrated moving average (3, 1, 0) (0, 1, 1)12 model, and the statistical process-control charts detected no measles epidemics during September 2007-August 2009. The two-stage monitoring system performed well to capture the measles dynamics in Bangladesh without detection of an epidemic because of high measles-vaccination coverage. [ABSTRACT FROM AUTHOR]

Published
2011

173. Millimetre-wave studies on the high-spin molecules Cr10(OMe)20(O2CCMe3)10 and Cr12O9(OH)3(O2CCMe3)15

Author

Sharmin, S., Ardavan, A., Blundell, S.J., and Coldea, A.I.

Subjects
*ELECTRON paramagnetic resonance, *PARTICLES (Nuclear physics), *SPECTRUM analysis, *TEMPERATURE
Abstract

Abstract: We report millimetre-wave electron spin resonance (ESR) measurements on single crystals of the high-spin molecules Cr10(OMe)20(O2CCMe3)10 and Cr12O9(OH)3(O2CCMe3)15 within a temperature range of 1.4K to 50K and in magnetic fields of up to 5 Tesla. In our experiments it is possible to vary the orientation of the magnetic field with respect to the crystal axes, and thus to study the ESR lineshapes as a function of both temperature and angle. Our results confirm that Cr10(OMe)20(O2CCMe3)10 behaves as a single-molecule magnet with S= 15 and D= -0.03K, while Cr12O9(OH)3(O2CCMe3)15 has S =6 and D ∼0.1K. A comparison of the experimental spectra with numerical simulations gives good agreement at low temperatures. At higher temperatures, we observe a narrowing of the ESR spectrum that is not explained by simple models. [Copyright &y& Elsevier]

Published
2005
Full Text
View/download PDF

175. Determinants of MS re-activation after discontinuing therapies

Author

Husin, H., Wallace, J., Malpas, C., Sharmin, S., Horakova, D., Havrdova, E. Kubala, Izquierdo, G., Eichau, S., Prat, A., Girard, M., Duquette, P., Trojano, M., Grammond, P., Lugaresi, A., Onofrj, M., Ozakbas, S., Butzkueven, H., Sola, P., Ferraro, D., Alroughani, R., Grand Maison, F., Terzi, M., Lechner-Scott, J., Boz, C., Hupperts, R., Shaygannejad, V., Bergamaschi, R., Pucci, E., Pesch, V., Hodgkinson, S., Mccombe, P., Granella, F., Slee, M., Wijmeersch, B., Karabudak, R., Prevost, J., Petersen, T., Spitaleri, D., Barnett, M., Solaro, C., Iuliano, G., Verheul, F., Ramo-Tello, C., Recai Turkoglu, Fernandez Bolanos, R., Butler, E., Macdonell, R., Soysal, A., Betancur, M. Moreno, and Kalincik, T.

176. Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models

Author

Diouf, I., Malpas, C., Sharmin, S., Izanne Roos, Horakova, D., Havrdova, E. K., Patti, F., Shaygannejad, V., Ozakbas, S., Izquierdo, G., Eichau, S., Onofrj, M., Lugaresi, A., Alroughani, R., Duquette, P., Terzi, M., Boz, C., Grand Maison, F., Hamdy, S., Sola, P., Grammond, P., Turkoglu, R., Skibina, O., Buzzard, K., Yamout, B., Altintas, A., Gerlach, O., Pesch, V., Blanco, Y., Maimone, D., Lechner-Scott, J., Bergamaschi, R., Karabudak, R., Barnet, M., Hughes, S., Sa, M. J., Kappos, L., Hodgkinson, S., Butzkueven, H., Prevost, J., Laureys, G., Moore, F., and Kalincik, T.

179. Aggressive form of multiple sclerosis can be predicted early after disease onset

Author

Malpas, C. B., Manouchehrinia, A., Sharmin, S., Izanne Roos, Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Eichau, S., Bergamaschi, R., Sola, P., Ferraro, D., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Grand Maison, F., Ozakbas, S., Pesch, V., Granella, F., Hupperts, R., Pucci, E., Boz, C., Iuliano, G., Sidhom, Y., Gouider, R., Spitaleri, D., Butzkueven, H., Soysal, A., Petersen, T., Verheul, F., Karabudak, R., Turkoglu, R., Ramo-Tello, C., Terzi, M., Cristiano, E., Slee, M., Mccombe, P., Macdonell, R., Fragoso, Y., Olascoaga, J., Altintas, A., Olsson, T., Hillert, J., and Kalincik, T.

181. Disease reactivation following fingolimod cessation

Author

Malpas, C. B., Izanne Roos, Sharmin, S., Butzkueven, H., Kappos, L., Patti, F., Alroughani, R., Horakova, D., Havrdova, E. K., Izquierdo, G., Eichau, S., Hodgkinson, S., Grammond, P., Lechner-Scott, J., and Kalincik, T.

183. Disability accrual in primary-progressive & secondary-progressive multiple sclerosis

Author

Harding-Forrester, S., Izanne Roos, Sharmin, S., Diouf, I., Malpas, C., Nguyen, A. -L, Moradi, N., Horakova, D., Havrdova, E. Kubala, Patti, F., Izquierdo, G., Eichau, S., Prat, A., Girard, M., Duquette, P., Onofrj, M., Lugaresi, A., Grand Maison, F., Weinstock-Guttman, B., Amato, M. P., Grammond, P., Gerlach, O., Ozakbas, S., Sola, P., Ferraro, D., Butzkueven, H., Lechner-Scott, J., Boz, C., Alroughani, R., Pesch, V., Cartechini, E., Terzi, M., Maimone, D., Ramo-Tello, C., Spitaleri, D., Kappos, L., Yamout, B., Sa, M., Slee, M., Blanco, Y., Bergamaschi, R., Butler, E., Iuliano, G., Granella, F., Sidhom, Y., Gouider, R., Ampapa, R., Wijmeersch, B., Karabudak, R., Prevost, J., Sanchez-Menoyo, J. L., Verheul, F., Mccombe, P., Castillo-Trivino, T., Macdonell, R., Altintas, A., Laureys, G., Hijfte, L., Walt, A., Vucic, S., Turkoglu, R., Barnett, M., Cristiano, E., Zakaria, M., Shaygannejad, V., Hodgkinson, S., Soysal, A., and Kalincik, T.

184. Comparison of the effectiveness of ocrelizumab vs interferons, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis

Author

Izanne Roos, Sharmin, S., Ozakbas, S., Horakova, D., Havrdova, E. K., Boz, C., Alroughani, R., Patti, F., Terzi, M., Lechner-Scott, J., Izquierdo, G., Eichau, S., Grammond, P., Buzzard, K., Skibina, O., Prat, A., Girard, M., Duquette, P., Soysal, A., Grand Maison, F., Kuhle, J., Walt, A., Butzkueven, H., Turkoglu, R., Butler, E., Laureys, G., Hijfte, L., Shaygannejad, V., Yamout, B., Khoury, S., Prevost, J., Sidhom, Y., Gouider, R., Cartechini, E., Sanchez-Menoyo, J. L., Sa, M. Jose, Macdonell, R., Pesch, V., Ramo-Tello, C., Mccombe, P., Willekens, B., Spitaleri, D., Ampapa, R., Al-Asmi, A., Slee, M., Besora, S., Malpas, C., and Kalincik, T.

185. Early clinical predictors of severe MS

Author

Malpas, C., Sharmin, S., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Bergamaschi, R., Sola, P., Ferraro, D., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Grand Maison, F., Ozakbas, S., Pesch, V., Granella, F., Hupperts, R., Pucci, E., Boz, C., Iuliano, G., Sidhom, Y., Gouider, R., Spitaleri, D., Butzkueven, H., Soysal, A., Petersen, T., Verheul, F., Karabudak, R., Recai Turkoglu, Ramo-Tello, C., Terzi, M., Cristiano, E., Slee, M., Mccombe, P., Macdonell, R., Fragoso, Y., Olascoaga, J., Altintas, A., and Kalincik, T.

186. Multiple Sclerosis Severity Score (MSSS) helps predict relapses and recovery from disability in patients treated for multiple sclerosis in the MSBase model

Author

Kister, I., Bacon, T. E., Malpas, C. B., Sharmin, S., Horakova, D., Havrdova, E. K., Patti, F., Izquierdo, G., Eichau, S., Ozakbas, S., Onofrj, M., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Sola, P., Ferraro, D., Alroughani, R., Terzi, M., Boz, C., Grand Maison, F., Bergamaschi, R., Hupperts, R., Sa, M. J., Kappos, L., Cartechini, E., Lechner-Scott, J., Pesch, V., Shaygannejad, V., Granella, F., Spitaleri, D., Iuliano, G., Maimone, D., Prevost, J., Soysal, A., Recai Turkoglu, Ampapa, R., Butzkueven, H., and Kalincik, T.

189. In vitro propagation of eggplant through meristem culture

Author

Sharmin, S. A., Ahmad Humayan Kabir, Mandal, A., Sarker, K. K., and Alam, M. F.

Subjects
shoot-tip, acclimatization, Solanum melongena L
Abstract

Meristem culture was done for developing an efficient protocol of production of eggplant clones. Shoot tips of 30-35 days old field grown eggplants were used for meristem isolation. Three cultivars viz. ‘Islampuri’, ‘Khatkhatia’ and ‘Katabegun’ were used in the present investigation as explants source. Surface sterilization of shoot tips was found to be the best in 0.1% HgCl2 solution for 3 minutes. For primary establishment of isolated apical meristem in MS liquid medium containing 2.0 mg l-1 BAP was found the best in cv Islampuri. BAP was also proved to be best for the primary establishment of isolated apical meristem in all the cultivars. Subsequent development of meristem derived shoot was achieved in MS semisolid medium containing either 2.0 mg l-1 BAP and 1.0 mg l-1 NAA or 1.0 mg l-1 BAP. For root development from meristem derived shoots, 1.0 mg l-1 IBA was found most responsive in cv. ‘Islampuri’ and ‘Khatkhatia’. Aft er transplantation, the in vitro plants showed normal growth.

191. Host gut-derived probiotic Lactobacillus sp. improves resistance of giant freshwater prawn Macrobrachium rosenbergii against Vibrio harveyi.

Author

Ahmmed, Fatema, Ahmmed, Mirja Kaizer, Khushi, Sharmin S., Sumon, Mohammad Saifuddin, Karamcheti, Sree Soundarya, and Sarower, Md. Golam

Subjects
*MACROBRACHIUM rosenbergii, *VIBRIO harveyi, *SHRIMPS, *LACTOBACILLUS, *PATHOGENIC bacteria, *BACTERIAL diseases, *WEIGHT gain
Abstract

The present study evaluated the effect of probiotic Lactobacillus sp. against pathogenic bacteria Vibrio harveyi in freshwater prawn Macrobrachium rosenbergii. The bacteria were isolated from the gut of prawn and identified using biochemical and PCR tests. Inoculation of probiotic (9 log CFU/g) and pathogenic bacteria (5 log CFU/g) mixture was employed for in vitro test. The in vivo challenge test was conducted in glass aquaria (45 × 30 × 30 cm3) and also in an earthen pond (70 m2, 1 m depth) for 8 weeks, individually. In both cases, only the treatment group was provided probiotic (9 log CFU/g) incorporated feed. Growth, digestibility, and immune response of prawn were determined. Both in the in vitro and in vivo test, V. harveyi growth was found to be reduced significantly at 8 hr (from 5 to 4 log CFU/g) and after 50 days (from 7 to 6 log CFU/g) of probiotic administration, respectively. In the pond, higher growth and better digestibility were found in the treatment group (WG%, 549. 30 ± 40.02%; SGR%, 3.12 ± 0.10%; amylase, 1.23 unit/mg; protease, 2.47 unit/mg) compared to the control group (WG%, 310.77 ± 18.68%; SGR%, 2. 35 ± 0.08%; 0.7 unit/mg; protease, 1.82 unit/mg). The immune response was found to be significantly different (P < 0.05) only for SGH (control, 22.76 ± 5.54%; probiotic, 19.32 ± 5.13%) and NGH (control, 75.12 ± 17.12%; probiotic, 78.12 ± 10.11%). Overall, the probiotic bacteria enhanced weight gain, digestibility, and immune response in the experimental prawn. Therefore, Lactobacillus sp. could be used as a potential probiotic for prawn culture against bacterial diseases. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

192. Author Correction: Injection of embryonic stem cell-derived macrophages ameliorates fibrosis in a murine model of liver injury.

Author

Haideri, Sharmin S., McKinnon, Alison C., Taylor, A. Helen, Kirkwood, Phoebe, Lewis, Philip J. Starkey, O'Duibhir, Eoghan, Vernay, Bertrand, Forbes, Stuart, and Forrester, Lesley M.

Subjects
EMBRYONIC stem cells, MACROPHAGES, LIVER injury prevention
Abstract

The following ethical statement was added to the end of the Methods section in the HTML and PDF versions of this Article: The animal experiments were approved and conducted in accordance to the UK Home Office regulations (Project Licence No.70/7847). Erratum to: doi:10.1038/s41536-017-0017-0 [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

193. Injection of embryonic stem cell derived macrophages ameliorates fibrosis in a murine model of liver injury.

Author

Haideri, Sharmin S., McKinnon, Alison C., Taylor, A. Helen, Kirkwood, Phoebe, Starkey Lewis, Philip J., O'Duibhir, Eoghan, Vernay, Bertrand, Forbes, Stuart, and Forrester, Lesley M.

Subjects
INJECTIONS, EMBRYONIC stem cells, MACROPHAGES, LIVER injury prevention, OBESITY
Abstract

Chronic liver injury can be caused by viral hepatitis, alcohol, obesity, and metabolic disorders resulting in fibrosis, hepatic scarring, and cirrhosis. Novel therapies are urgently required and previous work has demonstrated that treatment with bone marrow derived macrophages can improve liver regeneration and reduce fibrosis in a murine model of hepatic injury and fibrosis. Here, we describe a protocol whereby pure populations of therapeutic macrophages can be produced in vitro from murine embryonic stem cells on a large scale. Embryonic stem cell derived macrophages display comparable morphology and cell surface markers to bone marrow derived macrophages but our novel imaging technique revealed that their phagocytic index was significantly lower. Differences were also observed in their response to classical induction protocols with embryonic stem cell derived macrophages having a reduced response to lipopolysaccharide and interferon gamma and an enhanced response to IL4 compared to bone marrow derived macrophages. When their therapeutic potential was assessed in a murine, carbon tetrachloride-induced injury and fibrosis model, embryonic stem cell derived macrophages significantly reduced the amount of hepatic fibrosis to 50% of controls, down-regulated the number of fibrogenic myofibroblasts and activated liver progenitor cells. To our knowledge, this is the first study that demonstrates a therapeutic effect of macrophages derived in vitro from pluripotent stem cells in a model of liver injury. We also found that embryonic stem cell derived macrophages repopulated the Kupffer cell compartment of clodronate-treated mice more efficiently than bone marrow derived macrophages, and expressed comparatively lower levels of Myb and Ccr2, indicating that their phenotype is more comparable to tissue-resident rather than monocyte-derived macrophages. Stem cell-derived macrophages could treat liver fibrosis: Macrophages, a type of white blood cell, when derived from embryonic stem cells in the laboratory reduce fibrosis in chronic liver disease. Lesley Forrester and colleagues from the University of Edinburgh found murine embryonic stem-cell-derived macrophages (ESDM) were morphologically similar to bone marrow-derived macrophages (BMDM), previously found to reduce fibrosis and improve liver function in mice with induced liver injury. Using a novel technique, the team found ESDM engulfed fewer particles at a slower rate than BMDM, indicating ESDM were less inflammatory. A higher dose of ESDM was required to have the same effect of BMDM to help liver fibrosis regression. However, they were more efficient in repopulating mouse livers depleted of liver-specific macrophages and also significantly improved liver function, indicating ESDM were similar to resident macrophages in the liver and had therapeutic potential. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

195. Effects of repeatedly heated cooking oil consumption in mice: a study on health implications.

Author

Seema, I. J., Islam, R., John, A. S., Akter, F., Sultana, N., Sharmin, S., and Islam, M. R.

Subjects
*EDIBLE fats & oils, *VEGETABLE oils, *HIGH density lipoproteins, *MICE
Abstract

Background: Cooking oils are a major part of human diets, but repeated use of heated oils can have detrimental effects on consumer health. This study aims to investigate the impact of different heating grades of vegetable oils on the hemato-biochemical parameters and vital organs like the heart, liver, kidney, and intestine in mice. Methods: Thirty mice were randomly assigned to different treatment groups, including a control group (diet only), unheated cooking oil (UHCO) group, single heated cooking oil (SHCO) group, three times repeatedly heated cooking oil (3RHCO) group, and repeatedly heated cooking oil (ReHCO) group. Blood and organ samples were collected on day 31 to investigate hemato-biochemical parameters and histo-morphological alterations in response to the oil treatments. Results: The oil-treated groups showed significant (P<0.05) decreases in the total erythrocyte, leukocyte, and hemoglobin levels. Meanwhile, serum levels of total cholesterol, triglyceride, high-density lipoprotein, glucose, and creatinine increased significantly (P<0.05), while low-density lipoprotein and protein levels dropped markedly in the treatment groups. Severe histo-morphological alterations were also found in the liver (hepatocytic degeneration with hydropic change in the 3RHCO and ReHCO groups), kidney (glomerular atrophy with increased glomerular space, tubular degeneration, and lymphocytic infiltration in the SHCO, 3RHCO, and ReHCO groups), and colon (lymphocytic infiltration in the mucosal layer of ReHCO group). Conclusions: These findings suggest that the consumption of heated oils can have severe adverse effects on consumers' health, leading to alterations in blood chemistry and damage to vital organs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

196. Social inclusion, intersectionality, and profiles of vulnerable groups of young people seeking mental health support.

Author

Filia, K., Menssink, J., Gao, C. X., Rickwood, D., Hamilton, M., Hetrick, S. E., Parker, A. G., Herrman, H., Hickie, I., Sharmin, S., McGorry, P. D., and Cotton, S. M.

Abstract

Background: headspace centres provide enhanced primary mental healthcare for young people. A priority is to provide services for all young people irrespective of a range of social disadvantages or social exclusion. The aims of this study were to: (i) delineate extent of social inclusion across domains of housing, studying/employment, functioning, alcohol, and other drug use; and (ii) map profiles of young people deemed vulnerable to experiencing additional barriers to accessing services based on their social inclusion domains (e.g., those living in unstable housing, not in employment/education, and/or experiencing intersecting or multiple forms of disadvantage or difficulties), including detailing their clinical characteristics. Methods: Young people were recruited from five headspace centres. Data relevant to social inclusion were examined. Multivariate logistic regression models were used to determine overlap between vulnerable groups, functional, social, clinical, and behavioural factors. Results: 1107 young people participated, aged 12–25 years (M = 18.1 years, SD = 3.3), most living in stable housing (96.5%) and engaged in studying/employment (84.8%). Specific vulnerabilities were evident in young people with NEET status (15.2%); in unstable accommodation (3.5%); of culturally diverse backgrounds (CALD) (12.2%); living in regional areas (36.1%); and identifying as lesbian, gay, bisexual, transgender, intersex, queer/questioning, and asexual plus (LGBTIQA+; 28.2%). Higher levels of distress, substance use, functional impairment, and lower social support were reported by those who were NEET and/or in unstable housing. LGBTIQA+ status was associated with high distress, depressive symptoms, and suicidal ideation. Conclusions: Most participants reported good social support, stable housing, and engagement in work or education. Those deemed vulnerable were likely to experience social exclusion across multiple domains and reported more mental health problems. The co-occurrence of mental ill-health and social exclusion highlights the importance of integrated mental healthcare. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

197. Clinical and functional characteristics of a subsample of young people presenting for primary mental healthcare at headspace services across Australia.

Author

Filia, K., Rickwood, D., Menssink, J., Gao, C. X., Hetrick, S., Parker, A., Hamilton, M., Hickie, I., Herrman, H., Telford, N., Sharmin, S., McGorry, P., and Cotton, S.

Subjects
*YOUNG adults, *SUBSTANCE abuse, *QUALITY of life, *FUNCTIONAL assessment, *SUICIDAL ideation, *TREATMENT effectiveness
Abstract

Purpose: Headspace services provide treatment options to young people seeking mental healthcare. To obtain a better understanding of needs and characteristics of this population, and effectively evaluate services, we require novel youth-specific outcome measures. As part of our broad research program to establish such measures, a sample of young people were recruited and assessed. The study describes (i) methodology used to obtain clinical, functioning, and substance use characteristics of young people presenting to headspace services; and (ii) an overview of these characteristics.Methods: Young people presenting to headspace centres were recruited. Multidimensional information was obtained relating to clinical and functional outcomes, demographic information, and lifestyle factors.Results: 1107 young help-seeking individuals were recruited. Participants were most likely young adults aged M = 18.1 years, SD = 3.3, with diagnoses of depression and/or anxiety (76.6%, n = 801), engaged in work and study (84.9%, n = 890), and living with parent(s) (68.9%, n = 736). Impairments in functioning were moderate as indicated by the Social and Occupational Functioning Assessment Scale (M = 65.2, SD = 9.5), substance use was common (alcohol 62.7%, n = 665; illicit substances 30.5%, n = 324), and current suicidal ideation was reported by a third (33.6%, n = 358).Conclusions: A broad dataset was obtained providing an insight into key clinical, functional and quality of life characteristics of these individuals. We observed that young people present with complex problems, comorbid diagnoses, moderate levels of symptomatology, impairments in functioning, substance use, and suicidal ideation. This work provides the foundation for our broader research program aiming to develop novel, relevant and youth-specific, change and outcome measures. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

198. The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies

Author

Alexis Montcuquet, Henrik Kahr Mathiesen, Tomas Kalincik, Marc Girard, Karolina Hankiewicz, Marco Onofrj, Francois Grand Maison, Raed Alroughani, Mathilde Lefort, Olivier Gout, Jeannette Lechner-Scott, Marc Debouverie, Julie Prevost, Eva Havrdova, Olivier Casez, Per Soelberg Sørensen, Pierre Duquette, Jean Pelletier, Claudio Solaro, Alessandra Lugaresi, Francesco Patti, Emmanuelle Leray, Johanna Balslev Andersen, Bassem Yamout, Céline Labeyrie, Karen Schreiber, Eric Thouvenot, Nils Koch-Henriksen, Michael Broksgaard Jensen, Elisabeth Maillart, Chantal Nifle, Stephan Bramow, Pierre Clavelou, Bruno Stankoff, Olivier Heinzlef, Finn Sellebjerg, Abir Wahab, Mark Slee, Gilles Defer, Pierre Labauge, Melinda Magyari, Steve Vucic, Guillermo Izquierdo, Helmut Butzkueven, Peter Vestergaard Rasmussen, Bertrand Bourre, Maria Trojano, Franco Granella, Corinne Pottier, Jette L. Frederiksen, Olga Skibina, Recai Turkoglu, Ivania Patry, Pierre Grammond, Bart Van Wijmeersch, Eric Berger, Aurélie Ruet, Serkan Ozakbas, Jonathan Ciron, Tünde Csépány, Jean Philippe Camdessanche, Sandra Vukusic, Nicolas Maubeuge, David Laplaud, Cavit Boz, Christine Lebrun, Claudia C. Hilt Christensen, Patrizia Sola, Vahid Shaygannejad, Romain Casey, Murat Terzi, Philippe Cabre, Jérôme De Seze, Abdullatif Al-Khedr, Dana Horakova, Pamela A. McCombe, Daniele Spitaleri, Alexandre Prat, Gilles Edan, Hélène Zéphir, Aude Marousset, Sifat Sharmin, Diana Ferraro, Sara Eichau, Rana Karabudak, Thibault Moreau, Sellebjerg, Finn/0000-0002-1333-9623, Lugaresi, Alessandra/0000-0003-2902-5589, frederiksen, jette/0000-0003-1661-7438, Ciron, Jonathan/0000-0002-3386-6308, University of Copenhagen = Københavns Universitet (KU), University of Melbourne, Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Aarhus University Hospital, Rigshospitalet [Copenhagen], Copenhagen University Hospital, Centre de recherche en neurosciences de Lyon (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre hospitalier universitaire de Nantes (CHU Nantes), The MSBase Foundation is a not-for-profit organization that receives support from Biogen, Novartis, Merck, Roche, Teva and Sanofi Genzyme. The study was conducted separately and apart from the guidance of the sponsors. CORe received funding from NHMRC [1140766, 1129789, 1157717] to support studies of comparative effectiveness of MS therapies.OFSEP was supported by a grant provided by the French State and handled by the 'Agence Nationale de la Recherche,' within the framework of the 'Investments for the Future' program, under the reference ANR-10-COHO-002, by the Eugène Devic EDMUS Foundation against multiple sclerosis and by the ARSEP Foundation.DMSR did not receive any funding to collaborate in this study., ANR-10-COHO-0002,OFSEP,Observatoire Français de la Sclérose en Plaques(2010), Andersen J.B., Sharmin S., Lefort M., Koch-Henriksen N., Sellebjerg F., Sorensen P.S., Hilt Christensen C.C., Rasmussen P.V., Jensen M.B., Frederiksen J.L., Bramow S., Mathiesen H.K., Schreiber K.I., Horakova D., Havrdova E.K., Alroughani R., Izquierdo G., Eichau S., Ozakbas S., Patti F., Onofrj M., Lugaresi A., Terzi M., Grammond P., Grand Maison F., Yamout B., Prat A., Girard M., Duquette P., Boz C., Trojano M., McCombe P., Slee M., Lechner-Scott J., Turkoglu R., Sola P., Ferraro D., Granella F., Shaygannejad V., Prevost J., Skibina O., Solaro C., Karabudak R., Wijmeersch B.V., Csepany T., Spitaleri D., Vucic S., Casey R., Debouverie M., Edan G., Ciron J., Ruet A., Seze J.D., Maillart E., Zephir H., Labauge P., Defer G., Lebrun C., Moreau T., Berger E., Clavelou P., Pelletier J., Stankoff B., Gout O., Thouvenot E., Heinzlef O., Al-Khedr A., Bourre B., Casez O., Cabre P., Montcuquet A., Wahab A., Camdessanche J.-P., Marousset A., Patry I., Hankiewicz K., Pottier C., Maubeuge N., Labeyrie C., Nifle C., Leray E., Laplaud D.A., Butzkueven H., Kalincik T., Vukusic S., Magyari M., University of Copenhagen = Københavns Universitet (UCPH), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Bordeaux [Bordeaux], CHU Strasbourg, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Universitaire de Nice (CHU Nice), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Clermont-Ferrand, Hôpital de la Timone [CHU - APHM] (TIMONE), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital de la Fondation Ophtalmologique Adolphe de Rothschild [AP-HP], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut de Génomique Fonctionnelle (IGF), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy], CHU Amiens-Picardie, CHU Rouen, Normandie Université (NU), Centre Hospitalier Universitaire [Grenoble] (CHU), CHU de la Martinique [Fort de France], CHU Limoges, Hôpital Henri Mondor, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier de Saint-Denis [Ile-de-France], Centre hospitalier universitaire de Poitiers (CHU Poitiers), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), and Centre Hospitalier de Versailles André Mignot (CHV)

Subjects
medicine.medical_specialty, Fingolimod, Head-to-head comparison, Multiple sclerosis, Natalizumab, Treatment effectiveness, [SDV]Life Sciences [q-bio], Relapse rate, 03 medical and health sciences, Multiple Sclerosis, Relapsing-Remitting, 0302 clinical medicine, Internal medicine, Fingolimod Hydrochloride, Epidemiology, Humans, Medicine, Multiple sclerosi, Registries, 030212 general & internal medicine, business.industry, Hazard ratio, General Medicine, medicine.disease, 3. Good health, First relapse, Treatment Outcome, Neurology, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Neurology (clinical), business, Immunosuppressive Agents, 030217 neurology & neurosurgery, medicine.drug
Abstract

Background: Natalizumab and fingolimod were the first preparations recommended for disease breakthrough in priorly treated relapsing-remitting multiple sclerosis. Of three published head-to-head studies two showed that natalizumab is the more effective to prevent relapses and EDSS worsening. Methods: By re-analyzing original published results from MSBase, France, and Denmark using uniform meth-odologies, we aimed at identifying the effects of differences in methodology, in the MS-populations, and at re-evaluating the differences in effectiveness between the two drugs. We gained access to copies of the individual amended databases and pooled all data. We used uniform inclusion/ exclusion criteria and statistical methods with Inverse Probability Treatment Weighting. Results: The pooled analyses comprised 968 natalizumab-and 1479 fingolimod treated patients. The on-treatment natalizumab/fingolimod relapse rate ratio was 0.77 (p=0.004). The hazard ratio (HR) for a first relapse was 0.82 (p=0.030), and the HR for sustained EDSS improvement was 1.4 (p=0.009). There were modest differences between each of the original published studies and the replication study, but the conclusions of the three original studies remained unchanged: in two of them natalizumab was more effective, but in the third there was no difference between natalizumab and fingolimod. Conclusion: The results were largely invariant to the epidemiological and statistical methods but differed between the MS populations. Generally, the advantage of natalizumab was confirmed. BiogenBiogen; NovartisNovartis; MerckMerck & Company; RocheRoche Holding; Teva; Sanofi GenzymeSanofi-AventisGenzyme Corporation; NHMRCNational Health and Medical Research Council of Australia [1140766,1129789, 1157717]; French State; Agence Nationale de la Recherche-French National Research Agency (ANR)European Commission [ANR-10-COHO-002]; Eugene Devic EDMUS Foundation; ARSEP Foundation

Published
2021
Full Text
View/download PDF

199. Assessing the impact of chrysene-sorbed polystyrene microplastics on different life stages of the mediterranean mussel mytilus galloprovincialis

Author

Elena Fabbri, Paola Valbonesi, Alessandro G. Rombolà, Marco Capolupo, Sadia Sharmin, Daniele Fabbri, Capolupo M., Rombola A.G., Sharmin S., Valbonesi P., Fabbri D., and Fabbri E.

Subjects
Chrysene, Mediterranean mussel, Technology, Microplastics, animal structures, QH301-705.5, QC1-999, bivalves, medicine.disease_cause, chemistry.chemical_compound, medicine, Ingestion, General Materials Science, Food science, Biology (General), POPs, QD1-999, Instrumentation, Chemical sorption, Fluid Flow and Transfer Processes, biology, Chemistry, Physics, Process Chemistry and Technology, fungi, Bivalve, General Engineering, biomarkers, Mussel, Biomarker, Engineering (General). Civil engineering (General), biology.organism_classification, Mytilus, Computer Science Applications, medicine.anatomical_structure, Gamete, Embryotoxicity, TA1-2040, Oxidative stress
Abstract

The sorption of organic pollutants to marine plastic litter may pose risks to marine organisms, notably for what concerns their intake and transfer through microplastic (MP) ingestion. This study investigated the effects of polystyrene MP loaded with chrysene (CHR) on early-stage and physiological endpoints measured in the Mediterranean mussel Mytilus galloprovincialis. The same concentrations of virgin microplastics (MP) and MP loaded with 10.8 µg CHR/mg (CHR-MP) were administered to mussel gametes/embryos (25 × 103 items/mL) and adults (5⋅× 103 items/L), further treatments included 0.1 mg/L of freely dissolved CHR and a second CHR concentration corresponding to that vehiculated by CHR-MP during exposure (3.78 µg/L and 0.73 ng/L for gamete/embryos and adults, respectively). None of the treatments affected gamete fertilization, while 0.1 mg/L CHR induced embryotoxicity. In adults, CHR-MP and MP similarly affected lysosomal membrane stability and neutral lipids and induced slight effects on oxidative stress endpoints. CHR affected tested endpoints only at 0.1 mg/L, with lysosomal, oxidative stress and neurotoxicity biomarkers generally showing greater alterations than those induced by CHR-MP and MP. This study shows that the CHR sorption on MP does not alter the impact of virgin MP on mussels and may pose limited risks compared to other routes of exposure.

Published
2021

200. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

Author

Mark Slee, Guillermo Izquierdo, Per Soelberg Soerensen, Karen Schreiber, Alexandre Prat, Francois Grand'Maison, Maria Trojano, Franco Granella, Pierre Duquette, David Laplaud, Elisabeth Maillart, Henrik Kahr Mathiesen, Bassem Yamout, Cavit Boz, Jean Pelletier, Corinne Pottier, Jette L. Frederiksen, Claudia Christina Pfleger, Tomas Kalincik, Olivier Gout, Daniele Spitaleri, Marc Girard, Marco Onofrj, Jérôme De Seze, Helmut Butzkueven, Emmanuelle Leray, Philippe Cabre, Julie Prevost, Abullatif Al-Khedr, Aude Maurousset, Eric Berger, Sifat Sharmin, Ivania Patry, Pamela A. McCombe, Patrizia Sola, Olga Skibina, Diana Ferraro, Pierre Clavelou, Francesco Patti, Finn Sellebjerg, Niels Koch-Henriksen, Alexis Montcuquet, Recai Turkoglu, Romain Casey, Bart Van Wijmeersch, Hélène Zéphir, Pierre Grammond, Dana Horakova, Davide Maimone, Serkan Ozakbas, Céline Labeyrie, Murat Terzi, Aurélie Ruet, Steve Vucic, Jonathan Ciron, Tünde Csépány, Nicolas Maubeuge, Bruno Stankoff, Mathilde Lefort, Katherine Buzzard, Karolina Hankiewicz, Jean-Philippe Camdessanché, Raed Alroughani, Michael Broksgaard Jensen, Pierre Labauge, Olivier Casez, Peter Vestergaard Rasmussen, Bertrand Bourre, Olivier Heinzlef, Gilles Defer, Gilles Edan, Alessandra Lugaresi, Abir Wahab, Melinda Magyari, Anneke van der Walt, Eva Havrdova, Johanna Balslev Andersen, Chantal Nifle, Stephan Bramow, Marc Debouverie, Thibault Moreau, Sandra Vukusic, Christine Lebrun-Frenay, Jeannette Lechner-Scott, Eric Thouvenot, Sharmin S., Lefort M., Andersen J.B., Leray E., Horakova D., Havrdova E.K., Alroughani R., Izquierdo G., Ozakbas S., Patti F., Onofrj M., Lugaresi A., Terzi M., Grammond P., Grand'Maison F., Yamout B., Prat A., Girard M., Duquette P., Boz C., Trojano M., McCombe P., Slee M., Lechner-Scott J., Turkoglu R., Sola P., Ferraro D., Granella F., Prevost J., Maimone D., Skibina O., Buzzard K., Van der Walt A., Van Wijmeersch B., Csepany T., Spitaleri D., Vucic S., Casey R., Debouverie M., Edan G., Ciron J., Ruet A., De Seze J., Maillart E., Zephir H., Labauge P., Defer G., Lebrun-Frenay C., Moreau T., Berger E., Clavelou P., Pelletier J., Stankoff B., Gout O., Thouvenot E., Heinzlef O., Al-Khedr A., Bourre B., Casez O., Cabre P., Montcuquet A., Wahab A., Camdessanche J.-P., Maurousset A., Patry I., Hankiewicz K., Pottier C., Maubeuge N., Labeyrie C., Nifle C., Laplaud D., Koch-Henriksen N., Sellebjerg F.T., Soerensen P.S., Pfleger C.C., Rasmussen P.V., Jensen M.B., Frederiksen J.L., Bramow S., Mathiesen H.K., Schreiber K.I., Magyari M., Vukusic S., Butzkueven H., Kalincik T., University of Melbourne, Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Copenhagen = Københavns Universitet (UCPH), École des Hautes Études en Santé Publique [EHESP] (EHESP), Charles University [Prague] (CU), Amiri hospital, Hospital Virgen Macarena, Dokuz Eylül Üniversitesi = Dokuz Eylül University [Izmir] (DEÜ), University of Catania [Italy], G.F. Ingrassia Hospital, Università degli studi 'G. d'Annunzio' Chieti-Pescara [Chieti-Pescara] (Ud'A), Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), Institute of Neurological Science of Bologna (IRCCS), Ondokuz Mayis University (OMU), American University of Beirut Faculty of Medicine and Medical Center (AUB), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), Karadeniz Technical University (KTU), Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), University of Queensland [Brisbane], Royal Brisbane & Women's Hospital [Brisbane, Australia] (RBWH), Flinders University [Adelaide, Australia], University of Newcastle [Callaghan, Australia] (UoN), Azienda Ospedaleria Universitaria di Modena, Università degli studi di Parma = University of Parma (UNIPR), University Hospital Parma, Monash University [Melbourne], The Alfred Hospital, Hasselt University (UHasselt), University of Debrecen Egyetem [Debrecen], San Giuseppe Moscati Hospital [Avellino, Italie], Westmead Hospital [Sydney], Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Hospices Civils de Lyon (HCL), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Fondation Eugène Devic EDMUS, Adaptation, mesure et évaluation en santé. Approches interdisciplinaires (APEMAC), Université de Lorraine (UL), Service de neurologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale (U1215 Inserm - UB), Université de Bordeaux (UB)-Institut François Magendie-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Strasbourg (Centre d’Investigation Clinique Plurithématique (CIC - P) ), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nouvel Hôpital Civil de Strasbourg-Hôpital de Hautepierre [Strasbourg], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Lille, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital Pasteur [Nice] (CHU), Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CHU Clermont-Ferrand, Neuro-Dol (Neuro-Dol), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Hôpital de la Timone [CHU - APHM] (TIMONE), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Fondation Ophtalmologique Adolphe de Rothschild [Paris], Institut de Génomique Fonctionnelle (IGF), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), CHI Poissy-Saint-Germain, Service de neurologie [Amiens], CHU Amiens-Picardie, Service de neurologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Centre Hospitalier Universitaire [Grenoble] (CHU), CHU de la Martinique [Fort de France], Service de Neurologie [CHU Limoges], CHU Limoges, CHU Henri Mondor [Créteil], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Service de Neurologie [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Hôpital Sud Francilien Corbeil Essonne, Centre Hospitalier de Saint-Denis [Ile-de-France], Centre Hospitalier René Dubos [Pontoise], Hôpital de la Milétrie, Centre hospitalier universitaire de Poitiers (CHU Poitiers), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Centre Hospitalier de Versailles André Mignot (CHV), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Aarhus University Hospital, Aalborg University [Denmark] (AAU), University Hospital of Northern Sealand, Rigshospitalet [Copenhagen], Copenhagen University Hospital, The Royal Melbourne Hospital, 1140766, National Health and Medical Research Council, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Copenhagen = Københavns Universitet (KU), Università degli Studi di Bologna, University of Bari Aldo Moro (UNIBA), University of Newcastle [Australia] (UoN), University of Parma = Università degli studi di Parma [Parme, Italie], University of Debrecen, Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Toulouse [Toulouse], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), CHU Henri Mondor, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Ondokuz Mayis University, Centre de recherche en neurosciences de Lyon (CRNL), Physiopathologie de la Plasticité Neuronale (Neurocentre Magendie - U1215 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA)-Hôpital de Hautepierre [Strasbourg]-Nouvel Hôpital Civil de Strasbourg, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), and Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Adult, Male, medicine.medical_specialty, Multiple Sclerosis, Internationality, Subgroup analysis, Rate ratio, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Natalizumab, Multiple Sclerosis, Relapsing-Remitting, 030225 pediatrics, Internal medicine, Secondary Prevention, Medicine, Humans, Immunologic Factors, Pharmacology (medical), Longitudinal Studies, Registries, 10. No inequality, Expanded Disability Status Scale, business.industry, Proportional hazards model, Fingolimod Hydrochloride, Multiple sclerosis, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, Middle Aged, medicine.disease, Fingolimod, 3. Good health, multiple sclerosis, sex, age, natalizumab, fingolimod, big data, Psychiatry and Mental health, Cohort, Female, Neurology (clinical), business, 030217 neurology & neurosurgery, Immunosuppressive Agents, medicine.drug, Follow-Up Studies
Abstract

Introduction: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting multiple sclerosis (RRMS). Whether this association is universal for all patient groups remains to be determined. Objective: The aim of this study was to compare the relative effectiveness of natalizumab and fingolimod in RRMS subgroups defined by the baseline demographic and clinical characteristics of interest. Methods: Patients with RRMS who were given natalizumab or fingolimod were identified in a merged cohort from three international registries. Efficacy outcomes were compared across subgroups based on patients’ sex, age, disease duration, Expanded Disability Status Scale (EDSS) score, and disease and magnetic resonance imaging (MRI) activity 12 months prior to treatment initiation. Study endpoints were number of relapses (analyzed withweighted negative binomial generalized linear model) and 6-month confirmed disability worsening and improvement events (weighted Cox proportional hazards model), recorded during study therapy. Each patient was weighted using inverse probability of treatment weighting based on propensity score. Results: A total of 5148 patients (natalizumab 1989; fingolimod 3159) were included, with a mean ± standard deviation age at baseline of 38 ± 10 years, and the majority (72%) were women. The median on-treatment follow-up was 25 (quartiles 15–41) months. Natalizumab was associated with fewer relapses than fingolimod (incidence rate ratio [IRR]; 95% confidence interval [CI]) in women (0.76; 0.65–0.88); in those aged ≤38 years (0.64; 0.54–0.76); in those withdisease duration ≤7 years (0.63; 0.53–0.76); in those with EDSS score 38 years (1.34; 1.04–1.73); those with disease duration >7 years (1.33; 1.01–1.74); those with EDSS score

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results